Company Profile

OraSure Technologies Inc (AKA: Epitope Inc ~ Immunologic Associates, Inc ~ STC Technologies)
Profile last edited on: 11/11/2023      CAGE: 0PNX6      UEI: Y79RWFLHWDM6

Business Identifier: Point-of-care and home diagnostic testing and sample collection technologies
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

220 East First Street
Bethlehem, PA 18015
   (610) 882-1820
Location: Multiple
Congr. District: 07
County: Northampton

Public Profile

Though long since having outgrown SBIR size standards, it is interesting to note that OraSure Technologies, Inc. (NASDAQ: OSUR), has matured to become a global leader in point-of-care and home diagnostic testing and sample collection technologies - work initiated in some measure from their SBIR involvement. Still of interest, in September 2021 it was announced that that the firm had been awarded a $109 million contract from the US Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), to build additional manufacturing capacity in the United States for InteliSwab™ COVID-19 rapid tests as part of the nation's pandemic preparedness plan. OraSure Technologies was originally formed as the result of a merger in 2000 between Epitope Inc and STC Technologies. The combined company works in the field of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In July 2012, the Company received approval from the U.S. Food and Drug Administration for the Company's OraQuick® In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market - making it the first and only rapid OTC HIV test approved in the U.S. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. In 2020, Orasure acquired another SBIR firm - UrSure.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2012 1 NIH $145,915
Project Title: Development of a Rapid Screening Point-Of-Care Test for Hiv, Hcv and Hbv
1999 2 NIH $1,110,047
Project Title: Development of Syphillis EIA Assays for Orasure or Serum
1992 2 NIH $533,718
Project Title: Rapid assay for HIV-1 anitbodies in saliva
1989 2 NIH $550,000
Project Title: Detection of aids virus (HTLV-III) by monoclonial antibodies
1988 1 NIH $50,000
Project Title: A non-toxic new drug active against giardia in vivo

Key People / Management

  Douglas A Michels -- President; Chief Executive Officer

  Denis R Burger

  Adolph J Ferro

  Michael J Gausling -- Founder and President

  J R George

  Stephen R Lee -- Executive Vice President; Chief Science Officer

  Nancy McLane -- Senior Vice President, Operations

  Ronald Spair -- Chief Operating Officer; Chief Financial Officer

  Thomas R Thieme

  Jill Thompson -- Senior Vice President, Business Development